High hopes that new immunotherapy drugs would prove to have benefits over toxic chemotherapy were dashed by large-scale trials, says David Crow. Pharmaceutical groups are now working on combinations of the immunotherapies and using them with chemo, but some pharma groups have suffered big losses and Wall Street has become sceptical

A transcript for this podcast is currently unavailable, view our accessibility guide.

Get alerts on Big Read podcast when a new story is published

Copyright The Financial Times Limited 2019. All rights reserved.
Reuse this content (opens in new window)

Comments have not been enabled for this podcast.

Follow the topics in this podcast